fluorouracil and Pain studies

Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.

Pain: An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.

Research Excerpts

Excerpt	Relevance	Reference
"Intralesional 5-fluorouracil (IL5-FU) has been used off-label for warts treatment; however, its use was limited by intense pain."	9.34	The efficacy of microneedling alone vs its combination with 5-fluorouracil solution vs 5-fluorouracil intralesional injection in the treatment of plantar warts. ( Ebrahim, HM; Ghonemy, S; Ibrahim Ali, M, 2020)
"External beam radiation with concurrent capecitabine is safe and tolerable for the treatment of pain from bone metastases of breast cancer origin."	9.17	Phase II study of concurrent capecitabine and external beam radiotherapy for pain control of bone metastases of breast cancer origin. ( Brenner, B; Fenig, E; Kaufman, B; Kundel, Y; Nasser, NJ; Pfeffer, RM; Purim, O; Rizel, S; Stemmer, SM; Sulkes, A; Symon, Z; Yerushalmi, R, 2013)
"To evaluate the effects of palliative chemotherapy with gemcitabine plus capecitabine (GemCap) on patient-reported outcomes measured using clinical benefit response (CBR) and quality-of-life (QOL) measures in patients with advanced biliary tract cancer."	9.13	Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer Research. ( Beretta, K; Borner, M; Caspar, CB; Dietrich, D; Gerber, D; Herrmann, R; Koeberle, D; Mingrone, W; Mora, O; Ruhstaller, T; Saletti, P; Strasser, F, 2008)
"COX-2 activation may mediate capecitabine induced toxicities, eg, hand-foot syndrome (HFS) and colorectal cancer progression, both of which may be improved by concurrent celecoxib."	9.12	Retrospective study of capecitabine and celecoxib in metastatic colorectal cancer: potential benefits and COX-2 as the common mediator in pain, toxicities and survival? ( Ayers, GD; Brown, T; Crane, CC; Curley, SA; Delcos, M; Feig, B; Janjan, N; Lin, EH; Morris, J; Rodriguez-Bigas, MA; Ross, A; Skibber, J; Vadhan, SR, 2006)
"The role of topical 5-fluorouracil (5-FU) in treating common warts is not well defined."	9.12	Topical 5-fluorouracil has no additional benefit in treating common warts with cryotherapy: a single-centre, double-blind, randomized, placebo-controlled trial. ( Chan, SW; Hon, KL; Lo, KK; Luk, NM; Tang, NL; Tang, WY; Wong, JK, 2006)
"Strontium-89 is an established alternative for the alleviation of bone pain in prostate cancer."	9.11	Palliation of bone pain in prostate cancer using chemotherapy and strontium-89. A randomized phase II study. ( Edgren, M; Ginman, C; Kälkner, KM; Nilsson, S; Nordström, B; Ryberg, M; Strang, P; Westlin, JE; Zimmermann, R, 2005)
"Different therapeutic modalities for ano-genital warts (AGWs) are available but data on the efficacy of 5-fluorouracil 0."	8.12	5-Fluorouracil 0.5%/salicylic acid 10% solution in the treatment of ano-genital warts. ( Ciccarese, G; Drago, F; Parodi, A, 2022)
" In this study, we investigated spontaneous pain and mechanical allodynia in a preclinical model of oral ulcerative mucositis after systemic administration of the chemotherapy drug 5-fluorouracil, using our proprietary pain assay system for conscious rats."	7.83	Distinct TRPV1- and TRPA1-based mechanisms underlying enhancement of oral ulcerative mucositis-induced pain by 5-fluorouracil. ( Goto, T; Harano, N; Hitomi, S; Inenaga, K; Inoue, H; Ito, M; Matoba, M; Miyano, K; Nodai, T; Ono, K; Uezono, Y; Watanabe, S; Yamaguchi, K, 2016)
"Hand-foot syndrome (HFS) is one of the most relevant dose-limiting adverse effects of capecitabine, an oral prodrug of 5-fluorouracil used in the standard treatment of breast and colorectal cancer."	7.77	A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome. ( Alonso, MR; Benítez, J; Caronia, D; de la Torre, J; Díaz-Rubio, E; García-Sáenz, JA; González-Neira, A; Martin, M; Moreno, LT; Pita, G; Sastre, J, 2011)
"Cutaneous warts are treated by different treatments with various efficacy."	7.11	Comparison of the efficacy of intralesional 5-fluorouracil/lidocaine/epinephrine injection with cryotherapy to treat common and palmoplantar warts: A randomized, controlled trial. ( Bagheri, Z; Sarani, MB; Sepaskhah, M, 2022)
"Hyperpigmentation was the most irritating side effect of 5-FU that occurred."	5.72	Comparative efficacy of intralesional 5 flurouracil and intralesional triamcinolone acetonide in localized plaque psoriasis. ( Attwa, E; Essam, R; Khater, MH; Selim, HM, 2022)
"5-Fluorouracil (5-FU) is an antineoplastic agent that is used topically to treat actinic keratoses."	5.62	Painful scrotal dermatitis secondary to topical 5-fluorouracil. ( Himes, RS; McKee, PH; Roberts, AA; Smith, RJ; Yi, JZ, 2021)
"Intralesional 5-fluorouracil (IL5-FU) has been used off-label for warts treatment; however, its use was limited by intense pain."	5.34	The efficacy of microneedling alone vs its combination with 5-fluorouracil solution vs 5-fluorouracil intralesional injection in the treatment of plantar warts. ( Ebrahim, HM; Ghonemy, S; Ibrahim Ali, M, 2020)
"A case of an exquisitely painful squamous cell carcinoma of the bladder is reported."	5.26	Dramatic palliation for painful, fixed bladder squamous cell carcinoma with 5-fluorouracil infusion. ( Confer, DJ; Gillespie, L; Smith, RB, 1977)
"External beam radiation with concurrent capecitabine is safe and tolerable for the treatment of pain from bone metastases of breast cancer origin."	5.17	Phase II study of concurrent capecitabine and external beam radiotherapy for pain control of bone metastases of breast cancer origin. ( Brenner, B; Fenig, E; Kaufman, B; Kundel, Y; Nasser, NJ; Pfeffer, RM; Purim, O; Rizel, S; Stemmer, SM; Sulkes, A; Symon, Z; Yerushalmi, R, 2013)
"Newer radiation techniques, and the application of continuous 5-FU exposure during radiation therapy using oral capecitabine may improve the treatment of anal cancer."	5.17	Simultaneous integrated boost-intensity modulated radiation therapy with concomitant capecitabine and mitomycin C for locally advanced anal carcinoma: a phase 1 study. ( Beijnen, JH; Boot, H; Cats, A; Deenen, MJ; Dewit, L; Schellens, JH, 2013)
"To evaluate the effects of palliative chemotherapy with gemcitabine plus capecitabine (GemCap) on patient-reported outcomes measured using clinical benefit response (CBR) and quality-of-life (QOL) measures in patients with advanced biliary tract cancer."	5.13	Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer Research. ( Beretta, K; Borner, M; Caspar, CB; Dietrich, D; Gerber, D; Herrmann, R; Koeberle, D; Mingrone, W; Mora, O; Ruhstaller, T; Saletti, P; Strasser, F, 2008)
"The role of topical 5-fluorouracil (5-FU) in treating common warts is not well defined."	5.12	Topical 5-fluorouracil has no additional benefit in treating common warts with cryotherapy: a single-centre, double-blind, randomized, placebo-controlled trial. ( Chan, SW; Hon, KL; Lo, KK; Luk, NM; Tang, NL; Tang, WY; Wong, JK, 2006)
"COX-2 activation may mediate capecitabine induced toxicities, eg, hand-foot syndrome (HFS) and colorectal cancer progression, both of which may be improved by concurrent celecoxib."	5.12	Retrospective study of capecitabine and celecoxib in metastatic colorectal cancer: potential benefits and COX-2 as the common mediator in pain, toxicities and survival? ( Ayers, GD; Brown, T; Crane, CC; Curley, SA; Delcos, M; Feig, B; Janjan, N; Lin, EH; Morris, J; Rodriguez-Bigas, MA; Ross, A; Skibber, J; Vadhan, SR, 2006)
"Ninety patients with breast cancer were included; 70 patients received single agent paclitaxel either weekly or every 3 weeks and 20 received FAC (5-FU, doxorubicin, cyclophosphamide) chemotherapy."	5.11	Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. ( Arun, B; Booser, D; Bruera, E; Cleeland, CS; Fritsche, HA; Hortobagyi, GN; Ibrahim, N; Lara, J; Martinez, MM; Mendoza, TR; Pusztai, L; Reuben, JM; Rivera, E; Royce, M; Syed, A; Valero, V; Willey, JS, 2004)
"Strontium-89 is an established alternative for the alleviation of bone pain in prostate cancer."	5.11	Palliation of bone pain in prostate cancer using chemotherapy and strontium-89. A randomized phase II study. ( Edgren, M; Ginman, C; Kälkner, KM; Nilsson, S; Nordström, B; Ryberg, M; Strang, P; Westlin, JE; Zimmermann, R, 2005)
"Twenty-two patients, with locally advanced unresectable and/or metastatic pancreatic carcinoma, received weekly administration of cisplatin 40 mg m(-2), 5-fluorouracil 500 mg m(-2), epidoxorubicin 35 mg m(-2), 6S stereoisomer of leucovorin 250 mg m(-2) and glutathione 1."	5.09	Intensive weekly chemotherapy is not effective in advanced pancreatic cancer patients: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). ( Barni, S; Battelli, N; Casaretti, R; Cascinu, S; Catalano, G; Cellerino, R; Comella, G; Frontini, L; Labianca, R; Pirovano, M; Zonato, S, 1999)
"One hundred twenty-six patients with advanced symptomatic pancreas cancer completed a lead-in period to characterize and stabilize pain and were randomized to receive either gemcitabine 1,000 mg/m2 weekly x 7 followed by 1 week of rest, then weekly x 3 every 4 weeks thereafter (63 patients), or to fluorouracil (5-FU) 600 mg/m2 once weekly (63 patients)."	5.08	Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. ( Andersen, J; Burris, HA; Cripps, MC; Dorr, FA; Green, MR; Modiano, MR; Moore, MJ; Nelson, R; Portenoy, RK; Rothenberg, ML; Stephens, CD; Storniolo, AM; Tarassoff, P; Von Hoff, DD, 1997)
" Clinical benefit response (CBR), a new way to assess clinical efficacy based on marked, sustained improvement in pain intensity, analgesic consumption, and performance status, was used to evaluate a new chemotherapeutic agent, gemcitabine (2',2'-difluorodeoxycytidine [Gemzar])."	4.79	New developments in chemotherapy for patients with advanced pancreatic cancer. ( Rothenberg, ML, 1996)
" Pain is measured by facial grooming behavior stimulated by capsaicin, the alternation of body weight and food intake was also recorded to reflect the OM pain."	4.31	Sprayable NAHAO® hydrogel alleviates pain and accelerates rat oral mucositis wound healing. ( Ma, H; Mao, R; Tang, Y; Yan, H; Zhang, Y; Zhao, Y, 2023)
"Different therapeutic modalities for ano-genital warts (AGWs) are available but data on the efficacy of 5-fluorouracil 0."	4.12	5-Fluorouracil 0.5%/salicylic acid 10% solution in the treatment of ano-genital warts. ( Ciccarese, G; Drago, F; Parodi, A, 2022)
"The intent of this article is to evaluate the effect of oral cryotherapy on the prevention of oral mucositis and pain among patients with colorectal cancer undergoing fluorouracil-based chemotherapy."	3.88	Oral Cryotherapy: Prevention of Oral Mucositis and Pain Among Patients With Colorectal Cancer Undergoing Chemotherapy. ( Hsien Chan, CM; Idayu Mat Nawi, R; Lei Chui, P; Wan Ishak, WZ, 2018)
" In this study, we investigated spontaneous pain and mechanical allodynia in a preclinical model of oral ulcerative mucositis after systemic administration of the chemotherapy drug 5-fluorouracil, using our proprietary pain assay system for conscious rats."	3.83	Distinct TRPV1- and TRPA1-based mechanisms underlying enhancement of oral ulcerative mucositis-induced pain by 5-fluorouracil. ( Goto, T; Harano, N; Hitomi, S; Inenaga, K; Inoue, H; Ito, M; Matoba, M; Miyano, K; Nodai, T; Ono, K; Uezono, Y; Watanabe, S; Yamaguchi, K, 2016)
" Decreases in the rates of ascites and jaundice were confirmed by ultrasound and bilirubin levels."	3.80	Whole-liver radiotherapy concurrent with chemotherapy as a palliative treatment for colorectal patients with massive and multiple liver metastases: a retrospective study. ( Lu, K; Qiao, WB; Sun, D; Yin, H; You, QS; Zhang, HY, 2014)
"Hand-foot syndrome (HFS) is one of the most relevant dose-limiting adverse effects of capecitabine, an oral prodrug of 5-fluorouracil used in the standard treatment of breast and colorectal cancer."	3.77	A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome. ( Alonso, MR; Benítez, J; Caronia, D; de la Torre, J; Díaz-Rubio, E; García-Sáenz, JA; González-Neira, A; Martin, M; Moreno, LT; Pita, G; Sastre, J, 2011)
"Oral pain was assessed using a visual analogue scale alongside assessment of patients' perceptions and daily functional activities based on the Rotterdam Symptom Checklist."	3.30	Potential therapeutic effects of different mouthwashes for alleviation and treatment of oral complications of 5-fluorouracil-based chemotherapy in patients with colon cancer. ( Al-Taie, A; Koseoglu, A, 2023)
"Cutaneous warts are treated by different treatments with various efficacy."	3.11	Comparison of the efficacy of intralesional 5-fluorouracil/lidocaine/epinephrine injection with cryotherapy to treat common and palmoplantar warts: A randomized, controlled trial. ( Bagheri, Z; Sarani, MB; Sepaskhah, M, 2022)
"Different approaches are used aiming to improve these scars, including intralesional corticosteroids, surgery and more recently, laser therapy."	2.82	Laser therapy for treating hypertrophic and keloid scars. ( da Silva, CA; da Silva, EM; Kuczynski, U; Leszczynski, R; Pinto, ACPN, 2022)
" Follow-up for potential delayed adverse effects and efficacy is ongoing."	2.74	Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. ( Allegra, CJ; Atkins, JN; Azar, CA; Chu, L; Colangelo, LH; Fehrenbacher, L; Goldberg, RM; Lopa, SH; O'Connell, MJ; O'Reilly, S; Petrelli, NJ; Seay, TE; Sharif, S; Wolmark, N; Yothers, G, 2009)
"Fifty-four patients with T3/T4/N+ rectal cancers were treated on a Phase II trial using preoperative capecitabine and concomitant boost radiotherapy."	2.74	Temporal patterns of fatigue predict pathologic response in patients treated with preoperative chemoradiation therapy for rectal cancer. ( Cleeland, CS; Crane, CH; Das, P; Delclos, ME; Hundal, M; Janjan, NA; Krishnan, S; Lin, EH; Mendoza, TR; Park, HC; Vadhan-Raj, S; Wang, XS; Zhang, Y, 2009)
"Data of 211 patients with advanced pancreatic cancer who underwent FLEC regimen were analyzed."	2.73	Prognostic factors in patients with advanced pancreatic adenocarcinoma treated with intra-arterial chemotherapy. ( Ballardini, M; Bassi, C; Cantore, M; Fiorentini, G; Guadagni, S; Iacono, C; Mambrini, A; Orlandi, M; Pacetti, P; Torri, T, 2008)
"Seventy patients with advanced head and neck cancer were treated with vinorelbine and continuous 5-FU administered in a central venous catheter."	2.73	A phase II study using vinorelbine and continuous 5-fluorouracil in patients with advanced head and neck cancer. ( Adimi, P; Andersen, LJ; Bastholt, L; Larsen, S; Lindeløv, B; McCulloch, T; Serup-Hansen, E, 2007)
" When combined with synchronous therapy, it results in prolonged survival and an ameliorated quality of life."	2.67	Surgical palliation combined with synchronous therapy in pancreatic carcinoma. ( Chaichik, S; Inbar, M; Kahn, PJ; Kaplan, O; Rozin, R; Skornick, Y, 1990)
" day 1, 2, 23 and 24) was applied with the same schedule and dosage of radiation."	2.65	The value of two combined chemoradiotherapy approaches in the treatment of inoperable esophageal cancer. ( Dujmović, I; Kolarić, K; Roth, A, 1984)
"to prevent them from developing oral mucositis, is 4 people (95% CI 3 to 5)."	2.52	Interventions for preventing oral mucositis in patients with cancer receiving treatment: oral cryotherapy. ( Clarkson, JE; Glenny, AM; Littlewood, A; McCabe, MG; Riley, P; Worthington, HV, 2015)
"Hyperpigmentation was the most irritating side effect of 5-FU that occurred."	1.72	Comparative efficacy of intralesional 5 flurouracil and intralesional triamcinolone acetonide in localized plaque psoriasis. ( Attwa, E; Essam, R; Khater, MH; Selim, HM, 2022)
"5-Fluorouracil (5-FU) is an antineoplastic agent that is used topically to treat actinic keratoses."	1.62	Painful scrotal dermatitis secondary to topical 5-fluorouracil. ( Himes, RS; McKee, PH; Roberts, AA; Smith, RJ; Yi, JZ, 2021)
"Intestinal mucositis is a frequent side-effect of chemotherapy treatment."	1.43	Effects of acute chemotherapy-induced mucositis on spontaneous behaviour and the grimace scale in laboratory rats. ( Howarth, GS; Leach, MC; Lymn, KA; Preston, FL; Whittaker, AL, 2016)
"5-fluorouracil was given as continuous infusion 350 mg/m(2)/day five times weekly, and RHT (BSD-2000 system) was applied twice a week within 1 h after radiotherapy."	1.35	Radiochemotherapy in combination with regional hyperthermia in preirradiated patients with recurrent rectal cancer. ( Buecklein, V; Duehmke, E; Issels, RD; Milani, V; Pazos, M; Rahman, S; Schaffer, M; Schaffer, P; Tschoep, K; Wilkowski, R, 2008)
"Resiniferatoxin induced apoptosis in pancreatic cancer cells indicates that vanilloids may be useful in the treatment of human pancreatic cancer."	1.33	Vanilloids in pancreatic cancer: potential for chemotherapy and pain management. ( Büchler, MW; di Mola, FF; Di Sebastiano, P; Felix, K; Friess, H; Giese, NA; Hartel, M; Hinz, U; Mascetta, G; Selvaggi, F; Wente, MN, 2006)
"43 metastatic cancer patients received 190 portable infusors over 24 hours or more."	1.27	[Chemotherapy by ambulatory continuous infusion using a portable pump: a feasibility trial]. ( Benahmed, M; Carde, P; Laplanche, A; Renaux, J; Rouesse, J; Sancho-Garnier, H; Spielmann, M, 1985)
"Twenty-one patients with inoperable colon cancer in the pelvis were treated with intra-arterial 5-fluorouracil (5-FU) and mitomycin C, given bilaterally into the internal iliac arteries."	1.27	Palliation of pelvic recurrence of colorectal cancer with intra-arterial 5-fluorouracil and mitomycin. ( Chuang, VP; Claghorn, L; Mavligit, G; Patt, YZ; Peters, RE; Wallace, S, 1985)
"A case of an exquisitely painful squamous cell carcinoma of the bladder is reported."	1.26	Dramatic palliation for painful, fixed bladder squamous cell carcinoma with 5-fluorouracil infusion. ( Confer, DJ; Gillespie, L; Smith, RB, 1977)
"Four patients with primary inextirpable rectal cancer and 10 patients with locally recurrent rectal cancer have been treated."	1.26	Intraarterial infusion chemotherapy (5-fluorouracil) in patients with inextirpable or locally recurrent rectal cancer. ( Hafström, L; Jönsson, PE; Landberg, T; Owman, T; Sundkvist, K, 1979)

Research

Studies (75)

Authors

Clinical Trials (20)

Trial Overview

Trial Outcomes

Median Overall Survival Will be Determined.

Timeframe	Studies, this research(%)	All Research%
pre-1990	13 (17.33)	18.7374
1990's	8 (10.67)	18.2507
2000's	22 (29.33)	29.6817
2010's	22 (29.33)	24.3611
2020's	10 (13.33)	2.80

Authors	Studies
Panda, SS	1
Girgis, AS	1
Thomas, SJ	1
Capito, JE	1
George, RF	1
Salman, A	1
El-Manawaty, MA	1
Samir, A	1
Ciccarese, G	1
Parodi, A	1
Drago, F	1
Erlendsson, AM	1
Rosenberg, LK	1
Lerche, CM	1
Togsverd-Bo, K	1
Wiegell, SR	1
Karmisholt, K	1
Philipsen, PA	1
Hansen, ACN	1
Janfelt, C	1
Holmes, J	1
Rossi, A	1
Haedersdal, M	1
Sepaskhah, M	1
Sarani, MB	1
Bagheri, Z	1
Attwa, E	1
Khater, MH	1
Selim, HM	1
Essam, R	1
Leszczynski, R	1
da Silva, CA	1
Pinto, ACPN	1
Kuczynski, U	1
da Silva, EM	1
Zhao, Y	1
Mao, R	1
Yan, H	1
Zhang, Y	2
Ma, H	1
Tang, Y	1
Ghonemy, S	1
Ibrahim Ali, M	1
Ebrahim, HM	1
Al-Taie, A	1
Koseoglu, A	1
Yi, JZ	1
Himes, RS	1
Smith, RJ	1
McKee, PH	1
Roberts, AA	1
Idayu Mat Nawi, R	1
Lei Chui, P	1
Wan Ishak, WZ	1
Hsien Chan, CM	1
Deenen, MJ	1
Dewit, L	1
Boot, H	1
Beijnen, JH	1
Schellens, JH	1
Cats, A	1
Kundel, Y	1
Nasser, NJ	1
Purim, O	1
Yerushalmi, R	1
Fenig, E	1
Pfeffer, RM	1
Stemmer, SM	2
Rizel, S	1
Symon, Z	1
Kaufman, B	1
Sulkes, A	1
Brenner, B	1
Likhacheva, A	1
Jhingran, A	1
Bodurka, DC	1
Sun, C	1
Sam, M	1
Eifel, PJ	1
Nagashima, M	1
Ooshiro, M	1
Moriyama, A	1
Sugishita, Y	1
Kadoya, K	1
Sato, A	1
Kitahara, T	1
Takagi, R	1
Urita, T	1
Yoshida, Y	2
Tanaka, H	1
Oshiro, T	1
Okazumi, S	1
Katoh, R	1
Gaertner, J	1
Becker, G	1
Bernhard, J	2
Dietrich, D	3
Glimelius, B	2
Bodoky, G	2
Scheithauer, W	2
Herrmann, R	3
Yin, H	1
Lu, K	1
Qiao, WB	1
Zhang, HY	1
Sun, D	1
You, QS	1
Schapira, L	1
Blaszkowsky, LS	2
Cashavelly, BJ	1
Kim, CY	1
Riley, JP	1
Wold, MC	1
Ryan, DP	2
Penson, RT	1
Hoshino, S	1
Aisu, N	1
Naito, M	1
Tanimura, S	1
Mogi, A	1
Tanaka, T	1
Hirata, K	1
Tamura, K	1
Yamashita, Y	1
Middleton, G	1
Silcocks, P	1
Cox, T	1
Valle, J	1
Wadsley, J	1
Propper, D	1
Coxon, F	1
Ross, P	1
Madhusudan, S	1
Roques, T	1
Cunningham, D	3
Falk, S	1
Wadd, N	1
Harrison, M	1
Corrie, P	1
Iveson, T	2
Robinson, A	1
McAdam, K	1
Eatock, M	1
Evans, J	1
Archer, C	1
Hickish, T	2
Garcia-Alonso, A	1
Nicolson, M	1
Steward, W	1
Anthoney, A	1
Greenhalf, W	1
Shaw, V	1
Costello, E	1
Naisbitt, D	1
Rawcliffe, C	1
Nanson, G	1
Neoptolemos, J	1
Lee, MJ	1
Beith, J	1
Ward, L	1
Kilbreath, S	1
Whittaker, AL	1
Leach, MC	1
Preston, FL	1
Lymn, KA	1
Howarth, GS	1
Riley, P	1
Glenny, AM	1
Worthington, HV	1
Littlewood, A	1
Clarkson, JE	1
McCabe, MG	1
Yamaguchi, K	1
Ono, K	1
Hitomi, S	1
Ito, M	1
Nodai, T	1
Goto, T	1
Harano, N	1
Watanabe, S	1
Inoue, H	1
Miyano, K	1
Uezono, Y	1
Matoba, M	1
Inenaga, K	1
Browall, M	1
Brandberg, Y	1
Nasic, S	1
Rydberg, P	1
Bergh, J	1
Rydén, A	1
Xie, H	1
Eriksson, I	1
Wengström, Y	1
Gerber, D	2
Ruhstaller, T	2
Bajetta, E	1
Schüller, J	1
Saletti, P	2
Bauer, J	1
Figer, A	1
Pestalozzi, BC	1
Köhne, CH	1
Mingrone, W	2
Tàmas, K	1
Kornek, GV	1
Koeberle, D	2
Borner, M	1
Caspar, CB	1
Beretta, K	1
Strasser, F	1
Mora, O	1
Park, HC	1
Janjan, NA	1
Mendoza, TR	2
Lin, EH	2
Vadhan-Raj, S	1
Hundal, M	1
Delclos, ME	1
Crane, CH	1
Das, P	1
Wang, XS	1
Cleeland, CS	2
Krishnan, S	1
Lee, YJ	1
Lee, HJ	1
Jeong, KC	1
Kang, JG	1
Lee, SH	1
Kim, YT	1
Allegra, CJ	1
Yothers, G	1
O'Connell, MJ	1
Sharif, S	1
Colangelo, LH	1
Lopa, SH	1
Petrelli, NJ	1
Goldberg, RM	1
Atkins, JN	1
Seay, TE	1
Fehrenbacher, L	1
O'Reilly, S	1
Chu, L	1
Azar, CA	1
Wolmark, N	1
Lee, C	1
Saunders, M	1
Dipetrillo, T	1
Pricolo, V	1
Lagares-Garcia, J	1
Vrees, M	1
Klipfel, A	1
Cataldo, T	1
Sikov, W	1
McNulty, B	1
Shipley, J	1
Anderson, E	1
Khurshid, H	1
Oconnor, B	1
Oldenburg, NB	1
Radie-Keane, K	1
Husain, S	1
Safran, H	1
Saif, MW	1
Kaley, K	1
Caronia, D	1
Martin, M	1
Sastre, J	1
de la Torre, J	1
García-Sáenz, JA	1
Alonso, MR	1
Moreno, LT	1
Pita, G	1
Díaz-Rubio, E	1
Benítez, J	1
González-Neira, A	1
Chen, RC	1
Mamon, HJ	1
Ancukiewicz, M	1
Killoran, JH	1
Crowley, EM	1
Wo, JY	1
Hong, TS	1
Yatate, M	1
Kimura, M	1
Iwasaki, Y	1
Kamura, M	1
Yokoi, M	1
Uchitani, S	1
Mizumoto, T	1
Matsushita, H	1
Tebbutt, NC	2
Norman, A	2
Seymour, M	1
Harper, P	1
Maisey, N	1
Mochlinski, K	1
Prior, Y	1
Hill, M	2
Kelleher, M	1
Andreyev, J	1
Allen, M	1
Ito, Y	1
Ohtsu, A	1
Ishikura, S	1
Boku, N	1
Nihei, K	1
Ogino, T	1
Ikeda, H	1
Matsui, T	1
Kotake, K	1
Koyama, Y	1
Pusztai, L	1
Reuben, JM	1
Martinez, MM	1
Willey, JS	1
Lara, J	1
Syed, A	1
Fritsche, HA	1
Bruera, E	1
Booser, D	1
Valero, V	1
Arun, B	1
Ibrahim, N	1
Rivera, E	1
Royce, M	1
Hortobagyi, GN	1
Garrett, WV	1
Brown, JR	1
Pickering, D	1
Andrews, SM	1
Nilsson, S	1
Strang, P	1
Ginman, C	1
Zimmermann, R	1
Edgren, M	1
Nordström, B	1
Ryberg, M	1
Kälkner, KM	1
Westlin, JE	1
Hartel, M	1
di Mola, FF	1
Selvaggi, F	1
Mascetta, G	1
Wente, MN	1
Felix, K	1
Giese, NA	1
Hinz, U	1
Di Sebastiano, P	1
Büchler, MW	1
Friess, H	1
Luk, NM	1
Tang, WY	1
Tang, NL	1
Chan, SW	1
Wong, JK	1
Hon, KL	1
Lo, KK	1
Funakoshi, A	1
Sumii, T	1
Curley, SA	1
Crane, CC	1
Feig, B	1
Skibber, J	1
Delcos, M	1
Vadhan, SR	1
Morris, J	1
Ayers, GD	1
Ross, A	1
Brown, T	1
Rodriguez-Bigas, MA	1
Janjan, N	1
Poligone, B	1
Christensen, SR	1
Lazova, R	1
Heald, PW	1
Larsen, S	1
Serup-Hansen, E	1
Andersen, LJ	1
Lindeløv, B	1
McCulloch, T	1
Adimi, P	1
Bastholt, L	1
Mambrini, A	1
Bassi, C	1
Pacetti, P	1
Torri, T	1
Iacono, C	1
Ballardini, M	1
Orlandi, M	1
Guadagni, S	2
Fiorentini, G	2
Cantore, M	2
Milani, V	1
Pazos, M	1
Issels, RD	1
Buecklein, V	1
Rahman, S	1
Tschoep, K	1
Schaffer, P	1
Wilkowski, R	1
Duehmke, E	1
Schaffer, M	1
Lehman, JA	1
Shinn, GL	1
DesPrez, JD	1
Kolarić, K	1
Roth, A	1
Dujmović, I	1
Lokich, JJ	1
Moore, C	1
Ozols, RF	1
Speyer, JL	1
Jenkins, J	1
Myers, CE	1
Babaian, RJ	1
Hsu, SD	1
Maruyama, M	1
Takamatsu, H	1
Sugano, N	1
Katada, M	1
Ebuchi, M	1
Okusaka, T	1
Okada, S	1
Ishii, H	1
Nose, H	1
Nakasuka, H	1
Nakayama, H	1
Nagahama, H	1
Suwiński, R	1
Pilecki, B	1
Składowski, K	1
Swiatnicka, J	1
Zajusz, A	1
Przeorek, W	1
Utracka-Hutka, B	1
Jakus, G	1
Lange, B	1
Lange, D	1
Tarnawski, R	1
Maciejewski, B	1
Rothenberg, ML	2
Burris, HA	2
Moore, MJ	1
Andersen, J	1
Green, MR	1
Modiano, MR	1
Cripps, MC	1
Portenoy, RK	1
Storniolo, AM	1
Tarassoff, P	1
Nelson, R	1
Dorr, FA	1
Stephens, CD	1
Von Hoff, DD	1
Cascinu, S	1
Frontini, L	1
Comella, G	1
Barni, S	1
Labianca, R	1
Battelli, N	1
Casaretti, R	1
Zonato, S	1
Pirovano, M	1
Catalano, G	1
Cellerino, R	1
Pederzoli, P	1
Cornalba, G	1
Miserocchi, L	1
Frassoldati, A	1
Ceravolo, C	1
Smerieri, F	1
Muchmore, JH	1
Bos, AM	1
van der Graaf, WT	1
Willemse, PH	1
Confer, DJ	1
Smith, RB	1
Gillespie, L	1
Hafström, L	1
Jönsson, PE	1
Landberg, T	1
Owman, T	1
Sundkvist, K	1
Soukop, M	1
McVie, JG	1
Calman, KC	1
Kahn, PJ	1
Skornick, Y	1
Inbar, M	1
Kaplan, O	1
Chaichik, S	1
Rozin, R	1
Benahmed, M	1
Carde, P	1
Laplanche, A	1
Renaux, J	1
Rouesse, J	1
Spielmann, M	1
Sancho-Garnier, H	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Phase II, Randomised Study of Nivolumab as Consolidation Therapy in Patients With Locally Advanced, Unresectable Non-Small Cell Lung Cancer (Stage III) Who Have Not Progressed Following Neoadjuvant Chemotherapy Plus Nivolumab and Definitive Concurrent C[NCT04085250]	Phase 2	264 participants (Actual)	Interventional	2019-11-28	Active, not recruiting
Chemoradiation With Capecitabine for Palliation of Pain From Bone Metastasis[NCT01784393]	Phase 2	29 participants (Actual)	Interventional	2004-05-31	Completed
Gemcitabine Plus Capecitabine Versus Gemcitabine Alone In Advanced Pancreatic Cancer. A Randomized Phase III Trial[NCT00030732]	Phase 3	319 participants (Actual)	Interventional	2001-06-30	Completed
Capecitabine And Gemcitabine In Patients With Advanced Or Metastatic Biliary Tract Cancer, A Multicenter Phase II Trial[NCT00073905]	Phase 2	44 participants (Actual)	Interventional	2003-04-30	Completed
A Multi-center, II Phase，Randomized Controlled Clinical Study of Capecitabine Metronomic Chemotherapy After Gemcitabine Plus Capecitabine Standard Adjuvant Therapy for Stage II/III Pancreatic Cancer[NCT03959150]	Phase 2/Phase 3	231 participants (Anticipated)	Interventional	2020-01-05	Recruiting
Stereotactic Body Radiation Therapy With Sequential S-1 for Patients With Locally Advanced Pancreatic Cancer and Poor Medical Conditions --a Phase II Clinical Trial[NCT02704143]		63 participants (Actual)	Interventional	2016-02-29	Completed
Evaluation of the Effect of Ocoxin-Viusid® Nutritional Supplement in the Life Quality in Patients Diagnosed With Advanced Pancreatic Adenocarcinoma. Phase II[NCT03717298]	Phase 2	30 participants (Actual)	Interventional	2018-10-30	Completed
Randomized Phase III Study of Gemcitabine Versus TS-1 Versus Gemcitabine Plus TS-1 in Unresectable Advanced Pancreatic Cancer (With Local Progression or Metastasis)[NCT00498225]	Phase 3	834 participants (Actual)	Interventional	2007-07-31	Completed
Phase I Study of Soluble LAG-3 (IMP321) and Gemcitabine in Patients With Advanced Pancreas Cancer[NCT00732082]	Phase 1	18 participants (Actual)	Interventional	2009-02-28	Terminated (stopped due to Company manufacturing study drug was unable to continue production.)
Gimatecan (ST1481) as Second-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer: an Open-label, Randomized, Controlled Phase II Study[NCT04571489]	Phase 2	60 participants (Anticipated)	Interventional	2020-12-01	Not yet recruiting
Pharmacotyping of Patient-derived Pancreatic Cancer Organoids From Endoscopic Ultrasound-guided Biopsy as a Tool for Predicting Oncological Response[NCT05196334]		88 participants (Actual)	Observational	2021-07-01	Active, not recruiting
Postoperative and Long-term Survival in Relation to Life-expectancy After Pancreatic Surgery in Elderly Patients[NCT04893408]		1,556 participants (Actual)	Observational	2010-01-01	Completed
Sintilimab Plus Chemotherapy and Radiotherapy for Patients With Inoperable Pancreatic Cancer: a Single-arm, Exploratory, Phase II Trial[NCT06050317]	Phase 2	25 participants (Anticipated)	Interventional	2023-08-18	Recruiting
A Phase III, Open Label, Multicentre Randomised Clinical Study Comparing Acelarin (NUC-1031) With Gemcitabine in Patients With Metastatic Pancreatic Carcinoma[NCT03610100]	Phase 2/Phase 3	328 participants (Anticipated)	Interventional	2015-12-31	Suspended (stopped due to Suspended to recruitment following TSC review on efficacy and toxicities)
An Open Single-center Phase II Clinical Study of Fruquintinib Combined With Chemotherapy in Patients With Liver Metastases From Pancreatic Cancer[NCT05168527]	Phase 2	30 participants (Anticipated)	Interventional	2021-09-03	Recruiting
Phase II Trial of TAS-102 in Patients With Advanced, Refractory Pancreatic Adenocarcinoma[NCT04923529]	Phase 2	28 participants (Anticipated)	Interventional	2021-03-01	Recruiting
Systemic Therapy With a Loco-regional Treatment in Patients With Locally Advanced Pancreatic Cancer: The SMART Study[NCT04276857]		27 participants (Anticipated)	Interventional	2024-01-01	Not yet recruiting
A Multicenter, Open-label, ExploRatory Platform Trial to EValuate ImmunOtherapy Combinations With Chemotherapy for the Treatment of Patients With PreviousLy UnTreated MetastatIc Pancreatic AdenOcarciNoma (REVOLUTION)[NCT04787991]	Phase 1	45 participants (Anticipated)	Interventional	2021-08-09	Active, not recruiting
An Open-label, Multi-center, Phase 1b Study to Investigate the Safety and Tolerability of SLC-0111 (WBI-5111) in Combination With Gemcitabine in Metastatic Pancreatic Ductal Adenocarcinoma Subjects Positive for Carbonic Anhydrase IX[NCT03450018]	Phase 1/Phase 2	30 participants (Anticipated)	Interventional	2019-01-10	Recruiting
Randomized Phase II Trial Evaluating the Efficacy of a Sequential Treatment Gemcitabine Plus Nab-paclitaxel (Gembrax) Followed by Folfirinox Versus Folfirinox Alone in Patients Treated in First Metastatic Line Pancreatic Cancer[NCT05065801]	Phase 2	162 participants (Anticipated)	Interventional	2022-01-30	Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Median overall survival is calculated by Kaplan-Meier method. (NCT02704143)
Timeframe: 3 years

Number of Participants With Acute Toxicities Following SBRT

Intervention	months (Median)
Combination of Cyberknife With S-1	14.4

The acute toxicities are determined by RTOG Acute Radiation Morbidity Scoring Criteria. (NCT02704143)
Timeframe: Within 90 days after completion of SBRT

Number of Participants With Late Toxicities Following SBRT

Intervention	Participants (Count of Participants)
Combination of Cyberknife With S-1	9

The late toxicities are determined by RTOG/EORTC Late Radiation Morbidity Scoring Criteria. (NCT02704143)
Timeframe: 90 days after SBRT

One-year Overall Survival Rate

Intervention	Participants (Count of Participants)
Combination of Cyberknife With S-1	5

One-year overall survival rate is calculated by the ratio of number of patients surviving more than 1 year to the total number of patients enrolled. (NCT02704143)
Timeframe: 1 year

The Median Progression Free Survival Time Will be Determined.

Intervention	Participants (Count of Participants)
Combination of Cyberknife With S-1	46

Progression-free survival is the time from the date of enrollment to the confirmation of disease progression at any sites, including local progression or metastasis, or death from any causes, if this occurred before disease progression. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. (NCT02704143)
Timeframe: 3 years

The Quality of Life Will be Analyzed.

Intervention	months (Median)
Combination of Cyberknife With S-1	10.1

The analysis of quality of life is based on The European Organization for Reasearch and Treatment of Cancer (EORTC): Quality of Life Questionnare-Core 30 (QLQ-C30). Higher scores in function domains and global health status indicate better quality of life, while higher scores in symptom domains imply worse quality of life. The scale range of all domains of QLQ-C30 is 0-100 (the minimum and maximum score is 0 and 100 points, respectively). (NCT02704143)
Timeframe: 1 years

Intervention	units on a scale (Mean)
	Global health status	Physical functioning	Role functioning	Emotional functioning	Cognitive functioning	Social functioning	Fatigue	Nausea and vomiting	Pain	Dyspnea	Insomnia	Appetite loss	Constipation	Diarrhea	Financial difficulties
Combination of Cyberknife With S-1	50.0	64.2	54.8	68.5	73.8	74.6	46.7	55.3	48.7	9.5	19.0	59.2	13.2	13.7	31.2

Article	Year
Laser therapy for treating hypertrophic and keloid scars. The Cochrane database of systematic reviews, 2022, 09-26, Volume: 9 Topics: Adrenal Cortex Hormones; Adult; Aluminum; Atrophy; Carbon Dioxide; Child; Cicatrix, Hypertrophic; Di	2022
Interventions for preventing oral mucositis in patients with cancer receiving treatment: oral cryotherapy. The Cochrane database of systematic reviews, 2015, Dec-23, Issue:12 Topics: Adult; Antineoplastic Agents; Cryotherapy; Fluorouracil; Hematopoietic Stem Cell Transplantation; Hu	2015
[Treatment for recurrent colorectal cancer]. Nihon rinsho. Japanese journal of clinical medicine, 2003, Volume: 61 Suppl 7 Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Leucovor	2003
New developments in chemotherapy for patients with advanced pancreatic cancer. Oncology (Williston Park, N.Y.), 1996, Volume: 10, Issue:9 Suppl Topics: Analgesics; Antimetabolites, Antineoplastic; Clinical Trials, Phase II as Topic; Clinical Trials, Ph	1996

Article	Year
Synthesis, pharmacological profile and 2D-QSAR studies of curcumin-amino acid conjugates as potential drug candidates. European journal of medicinal chemistry, 2020, Jun-15, Volume: 196 Topics: Amino Acids; Analgesics; Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; An	2020
5-Fluorouracil 0.5%/salicylic acid 10% solution in the treatment of ano-genital warts. Dermatologic therapy, 2022, Volume: 35, Issue:5 Topics: Adult; Condylomata Acuminata; Female; Fluorouracil; Humans; Imiquimod; Male; Pain; Salicylic Acid; T	2022
Comparative efficacy of intralesional 5 flurouracil and intralesional triamcinolone acetonide in localized plaque psoriasis. Dermatologic therapy, 2022, Volume: 35, Issue:11 Topics: Drug Therapy, Combination; Fluorouracil; Humans; Hyperpigmentation; Injections, Intralesional; Keloi	2022
Sprayable NAHAO® hydrogel alleviates pain and accelerates rat oral mucositis wound healing. Journal of stomatology, oral and maxillofacial surgery, 2023, Volume: 124, Issue:1S Topics: Animals; Capsaicin; Cyclooxygenase 2; Dinoprostone; Fluorouracil; Humans; Hydrogels; Male; Matrix Me	2023
Painful scrotal dermatitis secondary to topical 5-fluorouracil. Dermatology online journal, 2021, Jun-15, Volume: 27, Issue:6 Topics: Administration, Topical; Aged; Drug Eruptions; Fluorouracil; Humans; Keratosis, Actinic; Male; Pain;	2021
Oral Cryotherapy: Prevention of Oral Mucositis and Pain Among Patients With Colorectal Cancer Undergoing Chemotherapy. Clinical journal of oncology nursing, 2018, 10-01, Volume: 22, Issue:5 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analgesics; Antifungal Agents; Antineoplastic Agents; Co	2018
Prospective study of symptom assessment among patients with cervical cancer during concurrent chemoradiotherapy with weekly cisplatin or every-3-week cisplatin and 5-fluorouracil. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2013, Volume: 23, Issue:8 Topics: Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Anxiety; Carcinoma; Chemoradiotherapy; Cispl	2013
Efficacy and tolerability of controlled-release oxycodone for oxaliplatin-induced peripheral neuropathy and the extension of FOLFOX therapy in advanced colorectal cancer patients. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2014, Volume: 22, Issue:6 Topics: Aged; Analgesics, Opioid; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dela	2014
Patients with advanced disease: the value of patient reported outcomes. Oncology research and treatment, 2014, Volume: 37, Issue:1-2 Topics: Capecitabine; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Karnofsky Performance Status	2014
Whole-liver radiotherapy concurrent with chemotherapy as a palliative treatment for colorectal patients with massive and multiple liver metastases: a retrospective study. Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:4 Topics: Aged; Antimetabolites, Antineoplastic; Ascites; Bilirubin; Colorectal Neoplasms; Combined Modality T	2014
Caring for one of our own. The oncologist, 2014, Volume: 19, Issue:5 Topics: Camptothecin; Caregivers; Diphosphonates; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle	2014
Administration of chemotherapy via the median cubital vein without implantable central venous access ports: port-free chemotherapy for metastatic colorectal cancer patients. International journal of clinical oncology, 2015, Volume: 20, Issue:2 Topics: Adenocarcinoma; Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined	2015
Lymphedema following taxane-based chemotherapy in women with early breast cancer. Lymphatic research and biology, 2014, Volume: 12, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Arm; Australia; Breast Neoplasms; Cyclophosphamide;	2014
Effects of acute chemotherapy-induced mucositis on spontaneous behaviour and the grimace scale in laboratory rats. Laboratory animals, 2016, Volume: 50, Issue:2 Topics: Animal Welfare; Animals; Facial Expression; Fluorouracil; Injections, Intraperitoneal; Male; Mucosit	2016
Distinct TRPV1- and TRPA1-based mechanisms underlying enhancement of oral ulcerative mucositis-induced pain by 5-fluorouracil. Pain, 2016, Volume: 157, Issue:5 Topics: Acetanilides; Anesthetics, Local; Animals; Anti-Bacterial Agents; Antimetabolites; Carcinosarcoma; C	2016
An unusual presentation of hand-foot syndrome at the hidden area: the scrotum and penis. Acta oncologica (Stockholm, Sweden), 2009, Volume: 48, Issue:4 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Administration Schedul	2009
Sickle cell crisis in a patient receiving capecitabine chemotherapy. Clinical oncology (Royal College of Radiologists (Great Britain)), 2010, Volume: 22, Issue:1 Topics: Adenocarcinoma; Anemia, Sickle Cell; Antineoplastic Agents, Phytogenic; Capecitabine; Colonic Neopla	2010
Pancreatic metastasis from colon carcinoma treated with radiotherapy with palliative benefit. JOP : Journal of the pancreas, 2010, Nov-09, Volume: 11, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Chemotherapy, Adjuvant; Col	2010
A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome. Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Apr-01, Volume: 17, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Base Sequence; Binding Sites; Breas	2011
Dose--volume effects on patient-reported acute gastrointestinal symptoms during chemoradiation therapy for rectal cancer. International journal of radiation oncology, biology, physics, 2012, Jul-15, Volume: 83, Issue:4 Topics: Aged; Antineoplastic Agents; Capecitabine; Chemoradiotherapy; Defecation; Deoxycytidine; Diarrhea; F	2012
[Reduction of vascular pain due to drop-infusion of oxaliplatin (L-OHP) in peripheral vein with heated infusion route]. Gan to kagaku ryoho. Cancer & chemotherapy, 2012, Volume: 39, Issue:4 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fluoroura	2012
Critical limb ischaemia associated with chemotherapy for breast cancer. Journal of the Royal Society of Medicine, 2004, Volume: 97, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Female; Fingers;	2004
Vanilloids in pancreatic cancer: potential for chemotherapy and pain management. Gut, 2006, Volume: 55, Issue:4 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Cell Division; Cell	2006
[Present and future home therapy in advanced stage of pancreatic cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:5 Topics: Ambulatory Care; Analgesics; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P	2006
Bazex syndrome (acrokeratosis paraneoplastica). Lancet (London, England), 2007, Feb-10, Volume: 369, Issue:9560 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Ear, External;	2007
Radiochemotherapy in combination with regional hyperthermia in preirradiated patients with recurrent rectal cancer. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2008, Volume: 184, Issue:3 Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Clinical Trials as Topic; Confidence I	2008
Chemotherapy for the control of pain in inoperable cancer. A report of intra-arterial infusion in four patients. The Ohio State medical journal, 1967, Volume: 63, Issue:8 Topics: Aged; Fluorouracil; Humans; Injections, Intra-Arterial; Male; Methotrexate; Middle Aged; Neoplasms;	1967
Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome. Annals of internal medicine, 1984, Volume: 101, Issue:6 Topics: Antineoplastic Agents; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule;	1984
Phase II trial of 5-FU administered Ip to patients with refractory ovarian cancer. Cancer treatment reports, 1984, Volume: 68, Issue:10 Topics: Abdomen; Drug Administration Schedule; Drug Evaluation; Female; Fluorouracil; Humans; Ovarian Neopla	1984
Chemotherapy of hormone-refractory carcinoma of prostate with 5-fluorouracil, adriamycin, and mitomycin C. Urology, 1984, Volume: 23, Issue:3 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Castration; Doxorubicin; Estro	1984
[Complications in the intraperitoneal chemotherapy with the implantable intraperitoneal port and the strategy for the prevention of the complication]. Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22, Issue:11 Topics: Aged; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Ascitic Fluid; Cisplati	1995
A new conservative approach to extravasation of anthracyclines with dimethylsulfoxide and dexrazoxane. Acta oncologica (Stockholm, Sweden), 2001, Volume: 40, Issue:4 Topics: Adult; Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; C	2001
Dramatic palliation for painful, fixed bladder squamous cell carcinoma with 5-fluorouracil infusion. The Journal of urology, 1977, Volume: 118, Issue:3 Topics: Carcinoma, Squamous Cell; Cobalt Radioisotopes; Fluorouracil; Humans; Infusions, Parenteral; Male; M	1977
Intraarterial infusion chemotherapy (5-fluorouracil) in patients with inextirpable or locally recurrent rectal cancer. American journal of surgery, 1979, Volume: 137, Issue:6 Topics: Adult; Aged; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Neoplasm Me	1979
Fluorouracil cardiotoxicity. British medical journal, 1978, May-27, Volume: 1, Issue:6124 Topics: Fluorouracil; Heart Diseases; Humans; Pain	1978
[Chemotherapy by ambulatory continuous infusion using a portable pump: a feasibility trial]. Bulletin du cancer, 1985, Volume: 72, Issue:1 Topics: Ambulatory Care; Antineoplastic Agents; Bleomycin; Bone Neoplasms; Cisplatin; Disposable Equipment;	1985
Fluorouracil and palmar-plantar erythrodysesthesia. Annals of internal medicine, 1989, Nov-15, Volume: 111, Issue:10 Topics: Erythema; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Pain	1989
Palliation of pelvic recurrence of colorectal cancer with intra-arterial 5-fluorouracil and mitomycin. Cancer, 1985, Nov-01, Volume: 56, Issue:9 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; C	1985
[Cancer of the body of the pancreas with hepatic metastases]. La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris, 1968, Jun-14, Volume: 44, Issue:29 Topics: Abdomen; Blindness; Catheterization; Cholangiography; Coma; Diagnosis, Differential; Fluorouracil; H	1968
Intra-arterial chemotherapy for patients with inoperable carcinoma of the pancreas. Proceedings of the Royal Society of Medicine, 1974, Volume: 67, Issue:11 Topics: Catheterization; Cyclophosphamide; Fluorouracil; Humans; Injections, Intra-Arterial; Jaundice; Metho	1974

fluorouracil and Pain